Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Clinical Therapeutics

Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis

Nicholas S. Britt, David J. Ritchie, Marin H. Kollef, Carey-Ann D. Burnham, Michael J. Durkin, Nicholas B. Hampton, Scott T. Micek
Nicholas S. Britt
aDepartment of Pharmacy, Barnes-Jewish Hospital, St. Louis, Missouri, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Ritchie
aDepartment of Pharmacy, Barnes-Jewish Hospital, St. Louis, Missouri, USA
bDepartment of Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, Missouri, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marin H. Kollef
cDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, Missouri, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carey-Ann D. Burnham
dDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA
eDepartment of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA
fDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Durkin
gDepartment of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas B. Hampton
hCenter for Clinical Excellence, BJC HealthCare, St. Louis, Missouri, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott T. Micek
aDepartment of Pharmacy, Barnes-Jewish Hospital, St. Louis, Missouri, USA
bDepartment of Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, Missouri, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.02400-17
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

In a retrospective analysis of 215 patients with carbapenem-resistant Pseudomonas aeruginosa sepsis, we observed a significantly higher risk of mortality associated with respiratory tract infection (risk ratio [RR], 1.20; 95% confidence interval [CI], 1.04 to 1.39; P = 0.010) and lower risk with urinary tract infection (RR, 0.80; 95% CI, 0.71 to 0.90; P = 0.004). Aminoglycoside monotherapy was associated with increased mortality, even after adjusting for confounders (adjusted RR, 1.72; 95% CI, 1.03 to 2.85; P = 0.037), consistent across multiple sites of infection.

TEXT

Infections due to carbapenem-resistant Gram-negative organisms represent an emerging threat to public health worldwide (1). The majority of carbapenem-resistant Gram-negative infections are caused by nonfermenters, most commonly, Pseudomonas aeruginosa (2). Multidrug-resistant P. aeruginosa is classified as a serious threat according to the most recent U.S. Centers for Disease Control and Prevention report, and 20% to 30% of clinical isolates are carbapenem resistant (1, 3). Mortality associated with these infections is high (20% to 50%), making optimal and timely treatment essential (4, 5). Unfortunately, the treatment of choice for carbapenem-resistant P. aeruginosa infection remains uncertain, and management is primarily based on pathogen-directed susceptibility patterns (6, 7).

We conducted a single-center retrospective cohort study at Barnes-Jewish Hospital (St. Louis, MO, USA), a 1,315-bed tertiary care academic medical center, to evaluate the comparative effectiveness of antibiotic agents used in the management of sepsis due to carbapenem-resistant P. aeruginosa infection (2012 to 2015). Inclusion criteria were age ≥18 years, hospital admission, carbapenem-resistant P. aeruginosa isolated from any site, and sepsis, defined as ≥2 systemic inflammatory response syndrome (SIRS) criteria (8). Exclusion criteria were cystic fibrosis (CF), polymicrobial infection, recurrent infection (only first case analyzed), and discharge to home alive without receiving appropriate targeted antibiotic therapy. Carbapenem resistance was defined as phenotypic nonsusceptibility to meropenem or imipenem. Clinical data were collected retrospectively from the electronic medical record. Comorbidities were identified by diagnosis codes as recorded by a treating physician. The primary outcome was all-cause in-hospital mortality. Baseline characteristics were compared by using the chi-squared test or Fisher's exact test for categorical data and Student's t test or the Mann-Whitney U test for continuous data. Multivariable log-binomial regression analysis was conducted to determine variables associated with mortality. Susceptibility testing was performed during routine clinical care using the disk diffusion method according to Clinical Laboratory and Standards Institute (CLSI) guidelines current at the time of infection (9). The Washington University in St. Louis institutional review board approved this study, and a P value of <0.05 was considered statistically significant.

A total of 2,736 patients with carbapenem-resistant Gram-negative infections were screened. Patients were excluded if they had <2 SIRS criteria (n = 1,700), CF (n = 91), recurrent infection (n = 392), lack of appropriate treatment before discharge alive (n = 64), and infection due to a Gram-negative organism other than P. aeruginosa (n = 274). A total of 215 patients with carbapenem-resistant P. aeruginosa sepsis were included in the final analysis. Overall, in-hospital mortality was 21.4% (46/215). Factors associated with mortality are shown in Table 1. The most common site of infection was the respiratory tract, which was associated with a greater risk of mortality than other sites of infection (28.8% [30/104] versus 14.4% [16/111]; risk ratio [RR], 1.20; 95% confidence interval [CI], 1.04 to 1.39; P = 0.010). The reason for this observation is unclear but may be related to difficulty in organism identification, leading to delayed appropriate therapy or suboptimal antibiotic penetration into the lung parenchyma. Conversely, urinary tract infections were associated with a lower risk of mortality than other sites of infection (6.5% [3/46] versus 25.4% [n = 43/169]; RR, 0.80; 95% CI, 0.71 to 0.90; P = 0.004), underscoring the importance of infection site on outcomes among patients with carbapenem-resistant P. aeruginosa infection.

View this table:
  • View inline
  • View popup
TABLE 1

Characteristics associated with all-cause in-hospital mortality among patients with sepsis due to carbapenem-resistant Pseudomonas aeruginosa

The most commonly utilized treatment modality was monotherapy with cefepime (n = 88). At our institution, cefepime is the treatment of choice for empirical therapy due to suspected P. aeruginosa infection, and dual Gram-negative coverage is not routinely utilized because of cefepime susceptibility rates of ∼90% among non-CF P. aeruginosa isolates. These susceptibility rates consistently exceed those of meropenem by 5% to 10%, and it is not uncommon to encounter cases of infection due to carbapenem-resistant P. aeruginosa with retained susceptibility to other antipseudomonal β-lactam agents, including cefepime or piperacillin-tazobactam (our unpublished data). In a recent study at the University of Pittsburgh Medical Center, 68% of carbapenem-resistant P. aeruginosa bloodstream isolates were susceptible to cefepime, and 57% were susceptible to piperacillin-tazobactam (7). Whether treatment of infections due to this susceptibility pattern requires use of more-toxic agents, such as aminoglycosides or polymyxins; more-expensive agents, such as novel β-lactam/β-lactamase inhibitors; or combinations of multiple active agents remains unclear (10). In the present study, we did not observe increased mortality associated with use of cefepime monotherapy (15.9% [14/88] versus 25.2% [32/127]; RR, 0.89; 95% CI, 0.77 to 1.02; P = 0.102) or piperacillin-tazobactam monotherapy (17.4% [8/46] versus 22.5% [38/169]; RR, 0.94; 95% CI, 0.80 to 1.10; P = 0.455) compared with mortality with all other therapies, suggesting that these agents may still be of utility in the management of select cases of carbapenem-resistant P. aeruginosa infection. There was no difference in mortality between patients receiving combination therapy and those receiving monotherapy (27.3% [3/11] versus 21.1% [43/204]; RR, 1.09; 95% CI, 0.75 to 1.57; P = 0.705), albeit this was a limited sample. Previous literature suggested a benefit of definitive treatment with combination therapy in carbapenem-resistant Enterobacteriaceae infection, but the data do not appear to support increased effectiveness against multidrug-resistant P. aeruginosa, consistent with our findings (10).

Aminoglycoside monotherapy was associated with an increased risk of mortality compared to other monotherapies (38.5% [15/39] versus 17.0% [28/165]; RR, 1.35; 95% CI, 1.04 to 1.75; P = 0.003). This association persisted after adjusting for confounding factors in multivariable log-binomial regression (adjusted RR, 1.72; 95% CI, 1.03 to 2.85; P = 0.037) (Table 2). Other factors significantly associated with an increased risk of mortality were vasopressor requirement and comorbidity burden (Table 2). In subgroup analyses by site of infection, aminoglycoside monotherapy was associated with a significantly increased risk of mortality in skin and soft tissue infections/osteomyelitis (50.0% [3/6] versus 13.0% [3/23]; RR, 1.74; 95% CI, 0.77 to 3.92; P = 0.047). Aminoglycoside monotherapy was associated with a nonsignificantly increased risk of mortality among subgroups of urinary tract (20.0% [1/5] versus 5.0% [2/40]; RR, 1.19; 95% CI, 0.76 to 1.85; P = 0.205), bloodstream/endovascular (33.3% [1/3] versus 12.5% [2/16]; RR, 1.31; 95% CI, 0.58 to 2.98; P = 0.364), and intraabdominal (40.0% [10/25] versus 24.7% [21/85]; RR, 1.25; 95% CI, 0.89 to 1.77; P = 0.135) infections. Only one patient with respiratory tract infection was treated with aminoglycoside monotherapy. Although aminoglycosides distribute well into various tissues, pathophysiological perturbations in critically ill patients with sepsis leading to increased volume of distribution and augmented renal clearance may decrease systemic aminoglycoside concentrations and prevent attainment of pharmacokinetic/pharmacodynamic targets versus isolates displaying MICs near the susceptibility breakpoint, potentially leading to poorer outcomes (11).

View this table:
  • View inline
  • View popup
TABLE 2

Multivariable log-binomial regression model of variables associated with all-cause in-hospital mortality among patients with carbapenem-resistant Pseudomonas aeruginosa sepsis

The present study had limitations. This was a retrospective analysis at a single center and likely lacked sufficient power to detect differences between some antibiotic regimens. Thus, prospective comparative effectiveness analyses of antibiotic agents for carbapenem-resistant P. aeruginosa infection are warranted. We included culture results from all body sites to evaluate the influence of this variable on patient outcomes; however, cultures from nonsterile sites may represent colonization rather than true infection. We attempted to overcome this by limiting analyses to patients with sepsis only and excluding known colonizers (i.e., CF). Thus, we expect any degree of misclassification to be negligible. This study did not feature analyses of antibiotic dosing strategies, which may have influenced the results.

In a retrospective analysis of patients with sepsis due to carbapenem-resistant P. aeruginosa, we evaluated associations between the site of infection and antibiotic choice on all-cause in-hospital mortality. We found an increased risk of mortality among patients with respiratory tract infection and a reduced risk of mortality among patients with urinary tract infection. Aminoglycoside monotherapy was associated with higher mortality than other treatments, and the magnitude of this effect was consistent across multiple infection sites. Although additional research is needed, the present study revealed important relationships between the site of infection, antibiotic selection, and mortality in patients with carbapenem-resistant P. aeruginosa infection, which should be considered in future studies.

ACKNOWLEDGMENTS

Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (KL2TR002346 to M.J.D.) and the Barnes-Jewish Hospital Foundation (M.H.K.).

The funders had no role in the study design, data collection and interpretation, or the decision to submit the work for publication.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Barnes-Jewish Hospital Foundation.

N.S.B. has served as a consultant on research grants from Merck & Co. and Gilead Sciences. D.J.R. has received speaking honoraria from Allergan, Astellas Pharma, and Theravance Biopharma. C.A.B. has received research support from bioMérieux, Cepheid, Theravance Biopharma, Accelerate Diagnostics, and Aperture Bio and consulting fees from Thermo Fisher and Monsanto. All other authors declare no conflicts of interest.

FOOTNOTES

    • Received 22 November 2017.
    • Returned for modification 13 December 2017.
    • Accepted 19 January 2018.
    • Accepted manuscript posted online 29 January 2018.
  • Copyright © 2018 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA.
  2. 2.↵
    1. Cai B,
    2. Echols R,
    3. Magee G,
    4. Arjona Ferreira JC,
    5. Morgan G,
    6. Ariyasu M,
    7. Sawada T,
    8. Nagata TD
    . 2017. Prevalence of carbapenem-resistant Gram-negative infections in the United States predominated by Acinetobacter baumannii and Pseudomonas aeruginosa. Open Forum Infect Dis 4:ofx176.
    OpenUrlCrossRef
  3. 3.↵
    1. Weiner LM,
    2. Webb AK,
    3. Limbago B,
    4. Dudeck MA,
    5. Patel J,
    6. Kallen AJ,
    7. Edwards JR,
    8. Sievert DM
    . 2016. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol 37:1288–1301. doi:10.1017/ice.2016.174.
    OpenUrlCrossRef
  4. 4.↵
    1. Liu Q,
    2. Li X,
    3. Li W,
    4. Du X,
    5. He JQ,
    6. Tao C,
    7. Feng Y
    . 2015. Influence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection: a meta-analysis. Sci Rep 5:11715. doi:10.1038/srep11715.
    OpenUrlCrossRef
  5. 5.↵
    1. Zhang Y,
    2. Chen XL,
    3. Huang AW,
    4. Liu SL,
    5. Liu WJ,
    6. Zhang N,
    7. Lu XZ
    . 2016. Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies. Emerg Microbes Infect 5:e27. doi:10.1038/emi.2016.22.
    OpenUrlCrossRef
  6. 6.↵
    1. Kanj SS,
    2. Kanafani ZA
    . 2011. Current concepts in antimicrobial therapy against resistant Gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 86:250–259. doi:10.4065/mcp.2010.0674.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Buehrle DJ,
    2. Shields RK,
    3. Clarke LG,
    4. Potoski BA,
    5. Clancy CJ,
    6. Nguyen MH
    . 2017. Carbapenem-resistant Pseudomonas aeruginosa bacteremia: risk factors for mortality and microbiologic treatment failure. Antimicrob Agents Chemother 61:pii=e01243-16. doi:10.1128/AAC.01243-16.
    OpenUrlCrossRef
  8. 8.↵
    1. Bone RC,
    2. Balk RA,
    3. Cerra FB,
    4. Dellinger RP,
    5. Fein AM,
    6. Knaus WA,
    7. Schein RM,
    8. Sibbald WJ
    . 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644–1655.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing; 26th informational supplement. CLSI document M100S-26. Clinical and Laboratory Standards Institute, Wayne, PA.
  10. 10.↵
    1. Hu Y,
    2. Li L,
    3. Li W,
    4. Xu H,
    5. He P,
    6. Yan X,
    7. Dai H
    . 2013. Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies. Int J Antimicrob Agents 42:492–496. doi:10.1016/j.ijantimicag.2013.09.002.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Varghese JM,
    2. Roberts JA,
    3. Lipman J
    . 2011. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit Care Clin 27:19–34. doi:10.1016/j.ccc.2010.09.006.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis
Nicholas S. Britt, David J. Ritchie, Marin H. Kollef, Carey-Ann D. Burnham, Michael J. Durkin, Nicholas B. Hampton, Scott T. Micek
Antimicrobial Agents and Chemotherapy Mar 2018, 62 (4) e02400-17; DOI: 10.1128/AAC.02400-17

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis
Nicholas S. Britt, David J. Ritchie, Marin H. Kollef, Carey-Ann D. Burnham, Michael J. Durkin, Nicholas B. Hampton, Scott T. Micek
Antimicrobial Agents and Chemotherapy Mar 2018, 62 (4) e02400-17; DOI: 10.1128/AAC.02400-17
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

carbapenem resistance
Pseudomonas aeruginosa
multidrug resistance
sepsis

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596